Sarvajit Chakravarty
Overview
Explore the profile of Sarvajit Chakravarty including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
629
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Elson D, Nguyen B, Korjeff N, Wilferd S, Puig-Sanvicens V, Jang H, et al.
Biochem Pharmacol
. 2023 Jul;
215:115706.
PMID: 37506922
Triple-negative breast cancer (TNBC) represents around 15% of the 2.26 million breast cancers diagnosed worldwide annually and has the worst outcome. Despite recent therapeutic advances, there remains a lack of...
2.
Elson D, Nguyen B, Bernales S, Chakravarty S, Jang H, Korjeff N, et al.
ACS Pharmacol Transl Sci
. 2023 Jul;
6(7):1028-1042.
PMID: 37470014
Triple-negative breast cancer (TNBC) remains a disease with a paucity of targeted treatment opportunities. The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that is involved in a wide...
3.
Pujala B, Ramachandran S, Sonawane M, Kamble M, Panpatil D, Adhikari S, et al.
Bioorg Med Chem Lett
. 2022 Sep;
75:128979.
PMID: 36089110
Compound 1 is a potent TGF-β receptor type-1 (TGFβR1 or ALK5) inhibitor but is metabolically unstable. A solvent-exposed part of this molecule was used to analogue and modulate cell activity,...
4.
Ramachandran S, Jadhavar P, Miglani S, Singh M, Kalane D, Agarwal A, et al.
Bioorg Med Chem Lett
. 2017 Apr;
27(10):2153-2160.
PMID: 28377059
Signaling via the receptor tyrosine kinase CSF1R is thought to play an important role in recruitment and differentiation of tumor-associated macrophages (TAMs). TAMs play pro-tumorigenic roles, including the suppression of...
5.
Alfaro J, Perez de Arce F, Belmar S, Fuentealba G, Avila P, Ureta G, et al.
J Pharmacol Exp Ther
. 2017 Mar;
361(2):312-321.
PMID: 28298527
Although new targeted therapies, such as ibrutinib and idelalisib, have made a large impact on non-Hodgkin's lymphoma (NHL) patients, the disease is often fatal because patients are initially resistant to...
6.
Pujala B, Agarwal A, Middya S, Banerjee M, Surya A, Nayak A, et al.
ACS Med Chem Lett
. 2016 Dec;
7(12):1161-1166.
PMID: 27994757
The aberrant activation of B-cells has been implicated in several types of cancers and hematological disorders. BTK and PI3Kδ are kinases responsible for B-cell signal transduction, and inhibitors of these...
7.
Ansari A, Satalkar S, Patil V, Shete A, Kaur S, Gupta A, et al.
Bioorg Med Chem Lett
. 2016 Dec;
27(2):217-222.
PMID: 27923618
EZH2 (enhancer of zeste homologue 2) is the catalytic subunit of the polycomb repressive complex 2 (PRC2) that catalyzes the methylation of lysine 27 of histone H3 (H3K27). Dysregulation of...
8.
Jadhavar P, Ramachandran S, Riquelme E, Gupta A, Quinn K, Shivakumar D, et al.
Bioorg Med Chem Lett
. 2016 Oct;
26(21):5222-5228.
PMID: 27717544
While enzalutamide and abiraterone are approved for treatment of metastatic castration-resistant prostate cancer (mCRPC), approximately 20-40% of patients have no response to these agents. It has been stipulated that the...
9.
Rai R, Banerjee M, Wong D, McCullagh E, Gupta A, Tripathi S, et al.
Bioorg Med Chem Lett
. 2016 Sep;
26(20):5103-5109.
PMID: 27614414
Temozolomide is a chemotherapeutic agent that is used in the treatment of glioblastoma and other malignant gliomas. It acts through DNA alkylation, but treatment is limited by its systemic toxicity...
10.
Byon C, Chakravarty S, Filer C, Jain R, Maniscalco M
Appl Radiat Isot
. 2015 Dec;
108:35-37.
PMID: 26686973
An efficient method is described to tritiate MDV3100 at high specific activity.